Clozapine-Associated Myocarditis in a Patient With Poor Metabolism During Fast Titration

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00079798" target="_blank" >RIV/65269705:_____/23:00079798 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/23:00130513

Výsledek na webu

<a href="https://journals.lww.com/psychopharmacology/citation/2023/03000/clozapine_associated_myocarditis_in_a_patient_with.20.aspx" target="_blank" >https://journals.lww.com/psychopharmacology/citation/2023/03000/clozapine_associated_myocarditis_in_a_patient_with.20.aspx</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1097/JCP.0000000000001666" target="_blank" >10.1097/JCP.0000000000001666</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Clozapine-Associated Myocarditis in a Patient With Poor Metabolism During Fast Titration

Popis výsledku v původním jazyce

To the EditorsSeveral articles concerning clozapine-associated myocarditis have been published in the Journal of Clinical Psychopharmacology . We would like to share our experience with this issue and highlight the rationale for routine monitoring of the markers of myocarditis.Clozapine-associated myocarditis is most likely to occur in the first (84%) or second month (5%) of therapy. It can be started by titration that is too fast for that individual patient. This is supposed to cause the development of clozapine-associated inflammation and cytokine release, further decreasing clozapine clearance (and elevating clozapine plasma level) resulting in increased clozapine-associated inflammation.The importance of metabolization status and titration speed as factors related to clozapine-associated myocarditis has been discussed in prior recent articles.

Název v anglickém jazyce

Clozapine-Associated Myocarditis in a Patient With Poor Metabolism During Fast Titration

Popis výsledku anglicky

To the EditorsSeveral articles concerning clozapine-associated myocarditis have been published in the Journal of Clinical Psychopharmacology . We would like to share our experience with this issue and highlight the rationale for routine monitoring of the markers of myocarditis.Clozapine-associated myocarditis is most likely to occur in the first (84%) or second month (5%) of therapy. It can be started by titration that is too fast for that individual patient. This is supposed to cause the development of clozapine-associated inflammation and cytokine release, further decreasing clozapine clearance (and elevating clozapine plasma level) resulting in increased clozapine-associated inflammation.The importance of metabolization status and titration speed as factors related to clozapine-associated myocarditis has been discussed in prior recent articles.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

<a href="/cs/project/LTAB19014" target="_blank" >LTAB19014: Porovnání snášenlivosti a efektivity 10 Hz a theta burstového stimulačního protokolu transkraniální magnetické stimulace v léčbě negativních příznaků u pacientů se schizofrenií</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Clinical Psychopharmacology

ISSN

0271-0749

e-ISSN

1533-712X

Svazek periodika

43

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

2

Strana od-do

186-187

Kód UT WoS článku

000971626500020

EID výsledku v databázi Scopus

2-s2.0-85149174805